Physicians assessed inflammation in the target joint using the following tenderness and swelling scales: tenderness rated as none, 'no pain'; mild, 'pain'; moderate, 'pain and winces'; severe, 'pain; winces and withdraws'; and swelling rated as none, 'no swelling'; mild, 'palpable'; moderate, 'visible'; and severe, 'bulging beyond the joint margins'.
All subjects developed a local reaction (erythema and induration) following vaccination with MVA85A, consistent with previous trials.,, Most subjects also experienced mild vaccine-site tenderness, pruritus and scaling (Table 2).
At this time point, patients treated with canakinumab 150 mg had a statistically significant lower score on the Likert scale for tenderness and for swelling compared with patients receiving triamcinolone acetonide and the difference between treatments remained statistically significant at seven days post-dose.
The general score of relationship quality is gained by adding the scale values of tenderness and of communication [ 21].
Tenderness was assessed on a scale from 0 to 2 at 7 sites in the trapezius area on left and right sides resulting in a maximum tenderness score of 28.
On stress testing both knees were stabile, the right knee showed maximum tenderness VAS 6-8 (visuanaloguegue scale: minimum 0, maximum pain 10 points) at the patellofemoral joint and the left knee VAS 5-7 athehe lateral tibiofemoral joint.
Women randomized to Prolutex were asked to describe the degree of itching and pain from injections, and the investigator assessed the last injection site using a rating scale for redness, tenderness, irritation and inflammation.
For the tender joint count, each joint was scored on a 0 3 scale with 3 being maximal tenderness (0 = no tenderness, 1 = pain on pressure, 2 = pain and winced, and 3 = winced and withdrew).
Pain intensity was quantified with a tenderness threshold (TT) and visual analog scale (VAS).
